Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2016 Apr 6;77(5):1039–1052. doi: 10.1007/s00280-016-3018-6

Figure 2.

Figure 2

Plasma (circles) and liver (squares) concentration time profiles following sorafenib administration to WT (black symbols) and Oatp1a/1b KO (red symbols) mice. The shaded region shows the variability in the disposition when SG Oatp1a/1b activity is decreased from the baseline value to 0.